login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
All US stocks
All Canadian stocks
All European stocks
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Account
Disclaimer
Affiliate
Contact
Privacy
ATAI LIFE SCIENCES NV (ATAI) Stock News
NASDAQ:ATAI -
NL0015000DX5
-
Common Stock
4.475
USD
-0.12 (-2.51%)
Last: 9/3/2025, 3:11:05 PM
Overview
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
ATAI Latest News, Press Relases and Analysis
All
Press Releases
6 hours ago - By: Zacks Investment Research
- Mentions:
HALO
Are Medical Stocks Lagging Halozyme Therapeutics (HALO) This Year?
6 days ago - By: atai Life Sciences
atai Life Sciences to Participate in September Investor Conferences
6 days ago - By: atai Life Sciences
atai Life Sciences to Participate in September Investor Conferences
16 days ago - By: Zacks Investment Research
Here's Why atai Life Sciences (ATAI) Is a Great 'Buy the Bottom' Stock Now
20 days ago - By: The Motley Fool
Atai Life Sciences Revenue Jumps 163%
2 months ago - By: atai Life Sciences
atai Life Sciences Announces $50 Million Private Placement Financing
20 days ago - By: atai Life Sciences
atai Life Sciences Reports Second Quarter 2025 Financial Results and Recent Corporate Updates
20 days ago - By: atai Life Sciences
atai Life Sciences Reports Second Quarter 2025 Financial Results and Recent Corporate Updates
a month ago - By: Yahoo Finance
H.C. Wainwright Lifts PT on Atai Life Sciences (ATAI) to $15 From $10
a month ago - By: Benzinga
- Mentions:
LION
LODE
SRPT
IONQ
This IonQ Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
a month ago - By: Benzinga
- Mentions:
LODE
IONQ
QBTS
This Atai Life Sciences Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Tuesday
a month ago - By: atai Life Sciences
Recognify Life Sciences Provides Update on Phase 2b Trial of Inidascamine in Patients with Cognitive Impairment Associated with Schizophrenia
a month ago - By: atai Life Sciences
Recognify Life Sciences Provides Update on Phase 2b Trial of Inidascamine in Patients with Cognitive Impairment Associated with Schizophrenia
2 months ago - By: Yahoo Finance
Aegis Capital Reaffirms Buy on Atai Life Sciences N.V. (ATAI) with $8 Target
2 months ago - By: Yahoo Finance
- Mentions:
GS
Canaccord Genuity Lifts Atai Life Sciences N.V. (ATAI)’s Price Target To $12, Maintains Buy Rating
2 months ago - By: FN Media Group LLC
- Mentions:
NYSE
CMPS
SAGE
MNMD
Global Neuro-Psychiatric Disorders & Treatment Market Projected to Reach $166 Billion by 2032
2 months ago - By: atai Life Sciences
atai Life Sciences Announces $50 Million Private Placement Financing
2 months ago - By: Bloomberg
Atai Shares Rise on Beckley’s Psychedelic Drug Study Success
2 months ago - By: atai Life Sciences
atai Life Sciences and Beckley Psytech Announce Positive Topline Results from the Phase 2b Study of BPL-003 in Patients with Treatment-Resistant Depression
2 months ago - By: atai Life Sciences
atai Life Sciences and Beckley Psytech Announce Positive Topline Results from the Phase 2b Study of BPL-003 in Patients with Treatment-Resistant Depression
2 months ago - By: Yahoo Finance
- Mentions:
UBS
T
T-PA
UBS Raised the PT on AT&T (T), Keeps a Buy Rating
2 months ago - By: Yahoo Finance
- Mentions:
OPK
ENTX
Piper Sandler Reiterates a Buy Rating on Opko Health (OPK) With a $3 PT
2 months ago - By: Yahoo Finance
Maxim Group Maintains a Buy on Atai Life Sciences (ATAI) With a $6 Price Target
3 months ago - By: Halper Sadeh LLC
- Mentions:
LNSR
ICAD
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates LNSR, ATAI, ICAD on Behalf of Shareholders
Please enable JavaScript to continue using this application.